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The industry donation of fluconazole to the South African 
public sector for the management of oesophageal candidiasis 
and cryptococcal meningitis was one of the earliest positive 
therapeutic steps in local public-service HIV management. In 
2004 it was estimated1 that training health care professionals in 
the use of this agent in 12 countries had cost over $2 million, 
and that the wholesale worth of the donated product was $100 
million. Programmatic success has been judged mainly using 
pharmaceutical logistical criteria such as medication volumes 
distributed and numbers of patients treated. Information on 
clinical outcomes is difficult to find.    
Among patients receiving prophylaxis after cryptococcal 
meningitis, the number of repeat scripts filled per patient 
may serve as a coarse measure of clinical outcome. Because 
the donation agreement requires patient-level recording of all 
fluconazole scripts dispensed, this information is available in 
the registers of all participating public-service pharmacies. 
Review process
The fluconazole donation programme has been in operation 
since 2003 at Frere and Cecilia Makiwane hospitals, now called 
the East London Hospital Complex (ELHC). The proportion of 
individuals returning for monthly script repeats from January 
2003 to December 2005 was extracted from the pharmacy 
department fluconazole registers. Trends in amphotericin usage 
in the ELHC and fluconazole availability at district level were 
assessed.  
Results
During the 3 years, 629 patients (mean age 34.5 years, standard 
deviation (SD) 8.98, 309 from hospital 1, 320 from hospital 2) 
were started on suppressive fluconazole therapy (200 mg daily) 
for cryptococcal meningitis. Only 31.5% of patients (N = 198) 
returned at 2 months of outpatient therapy, and at 4 months 
77% of the patients did not return for repeat scripts. After 1 
year, only 6% of patients were returning regularly to the ELHC.  
Amphotericin usage
Using failure to return for a further script as a surrogate for 
outcome, a Cox proportional hazards model was generated 
to compare outcomes between the two hospitals in the 
light of differential use of amphotericin B as initial therapy. 
During 2004, amphotericin was given to 91% of patients 
with cryptococcal meningitis at hospital 1 and to 56% at 
hospital 2. There was no difference in return rates between 
the two institutions (hazard ratio (HR) 1.01, 95% confidence 
interval (CI): 0.77 - 1.32). The use of fluconazole in the ELHC 
drainage region doubled during the study period, but even 
if all fluconazole dispensed at other sites was given entirely 
to patients initially managed at the ELHC, there would only 
have been sufficient fluconazole dispensed to treat patients 
for 7.3 months in 2003, 5.2 months in 2004 and 4.4 months in 
2005, assuming unrealistically that all patients were alive and 
on treatment and that the referring hospitals never initiated 
treatment. 
Only 62 patients were started on antiretroviral (ARV) therapy 
during this period (3.7% of those receiving fluconazole in 2003, 
10.1% in 2004, and 16.6% in 2005).
Discussion
This pharmacy-based retrospective observational survey raises 
concerns about adequacy of treatment adherence and highlights 
the scale of the epidemic. An unpublished audit in one of the 
two hospitals identified only 19 patients with cryptococcal 
meningitis in the 5 years up to 1996. Ten years later, the same 
hospital sees over 100 new patients per year.
Patients failing to return for follow-up may do so for at 
least four reasons: (i) they might be healthy in spite of lack of 
ongoing secondary prophylaxis; (ii) they might be obtaining 
secondary prophylaxis from another site; (iii) they might 
have been started on ARVs and reconstituted immunity such 
that their caregivers decided it was safe to stop secondary 
prophylaxis; or (iv) they might have died. Studies from 
elsewhere in Africa2,3 suggest that survival in the absence of 
secondary prophylaxis is poor. Patients may have obtained 
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very unlikely event that all the patients registered elsewhere 
in the region had started therapy at the ELHC, this would still 
not account for the discrepancy. Assuming that patients had 
no other access to fluconazole and were not on ARVs, and that 
there is a 50% annual mortality in patients without secondary 
prophylaxis, it is speculated that many of the patients failing to 
return for repeat scripts were no longer alive 2 years after their 
last visit, although pharmacy registry information is clearly 
inadequate to answer this.  
It is difficult to draw robust conclusions about the true 
clinical benefit to the country of the fluconazole donation 
based on the information routinely collected as part of the 
patient registration programme. The assumption that a 
therapy of proven value in clinical trials4 will necessarily 
provide equivalent benefits in real-world situations warrants 
verification for each individual medication.5 Vertical 
programmes driven by a national directorate may not be the 
best way of handling donations, and consideration should be 
given to a more integrated approach based on quantifiable 
clinical outcomes rather than a ‘get the pills to the patient’ 
paradigm. A similar pattern appears to be emerging with 
the ARV programme, where there is greater political and 
administrative emphasis on measuring roll-out than on 
quantifying sustained clinical benefit. 
The contribution of amphotericin to outcome in patients 
surviving to discharge may merit further study, and more 
emphasis on adherence counselling may be worthwhile. Of 
equal or greater urgency is the need to establish simple unified 
ways of formally measuring the clinical impact of the ARV 
programme in different health care environments around the 
country (and not just at pilot sites run by enthusiasts), rather 
than being faced later by similar unquantifiable doubts about 
overall efficacy.
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HPCSA waives penalty restoration fees for erased practitioners
The Health Professions Council of South Africa (HPCSA) is offering amnesty to all medical
doctors whose registration has lapsed and who want to re-register without having to pay
the penalty restoration fees.
Upon enquiry, the HPCSA informed SAMA that the Council agreed to a once-off waiver of
penalties for those practitioners, both local and abroad, who had  failed to pay their annual
registration fees on time, or who allowed their registration to lapse without informing Council.
The amnesty period started on 1 February 2007 and will expire on 30 April 2007.  The amnesty
applies to those practitioners – living locally and abroad – whose registrations have
lapsed and who have not practised for up to 2 years, as well as practitioners
who have been resident and practising in other countries.
Certain conditions apply for doctors to qualify for the waiver. These include:
• the duration of the lapse in registration (various categories exist)
• an assessment of professional skills and adherence to continuing professional development
• performing 100 hours of community service within 6 months at a public sector facility, and proof of compliance with this.
Practitioners whose registration has lapsed and who do not make use of this opportunity will
be liable for the full restoration penalty. According to an amended HPCSA regulation in
2005, the restoration fees payable by doctors who apply for the restoration of their
names to the register within 6 months after erasure are equivalent to twice the annual
fee for the current year, as well as the outstanding fees.
After a period of 6 months, but within 12 months of the erasure date, the amount is
equivalent to four times the applicable annual fee plus the outstanding fees. Those who
pay after more than 12 months from the erasure date will pay five times the
applicable annual fee for the current year, plus the outstanding fees.
Before the 2005 amended regulation, the restoration fees were as high as ten times the
annual HPCSA fee.
The annual fee of R834.68 payable by doctors registered with the HPCSA is due on 1
April 2007.
SAMA calls on members to distribute information about the amnesty to their colleagues
who live and work outside South Africa.
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